-
EP3481433
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3481433
| EP3481433 - AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 31.05.2024 Database last updated on 15.06.2024 | |
| Former | Grant of patent is intended Status updated on 23.01.2024 | ||
| Former | Examination is in progress Status updated on 22.01.2021 | ||
| Former | Request for examination was made Status updated on 12.04.2019 | ||
| Former | The international publication has been made Status updated on 12.01.2018 | Most recent event Tooltip | 31.05.2024 | (Expected) grant | published on 03.07.2024 [2024/27] | Applicant(s) | For all designated states University of Massachusetts One Beacon Street 31st Floor Boston, MA 02108 / US | For all designated states Massachusetts Eye & Ear Infirmary 243 Charles Street Boston, MA 02114 / US | [2019/20] | Inventor(s) | 01 /
MARSHAK-ROTHSTEIN, Ann 40 Royce Road Newton, MA 02459 / US | 02 /
GREGORY-KSANDER, Meredith 4 Longfellow Place 3606 Boston, MA 02114 / US | 03 /
KSANDER, Bruce 20 Staniford Street Boston, MA 02114 / US | [2019/20] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2024/27] |
| Former [2019/20] | Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 17824815.9 | 05.07.2017 | [2019/20] | WO2017US40735 | Priority number, date | US201662358541P | 05.07.2016 Original published format: US 201662358541 P | US201762511629P | 26.05.2017 Original published format: US 201762511629 P | [2019/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018009553 | Date: | 11.01.2018 | Language: | EN | [2018/02] | Type: | A1 Application with search report | No.: | EP3481433 | Date: | 15.05.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.01.2018 takes the place of the publication of the European patent application. | [2019/20] | Type: | B1 Patent specification | No.: | EP3481433 | Date: | 03.07.2024 | Language: | EN | [2024/27] | Search report(s) | International search report - published on: | US | 11.01.2018 | (Supplementary) European search report - dispatched on: | EP | 24.01.2020 | Classification | IPC: | A61K48/00, C07K14/005, C12N7/00, C12N15/86 | [2019/20] | CPC: |
A61K48/0075 (EP,KR,US);
A61K48/0058 (EP,KR,US);
A61K38/177 (EP,US);
A61K45/06 (US);
A61K48/00 (EP,US);
A61K9/0048 (US);
A61P27/06 (EP,KR,US);
C07K14/005 (EP,KR,US);
C07K14/70575 (EP,KR,US);
C12N15/86 (EP,KR,US);
C12N7/00 (US);
C12N2750/14132 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/20] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | AAV2-VERMITTELTE GENABGABE VON SFASL ALS NEUROPROTEKTIVE THERAPIE BEI GLAUKOM | [2019/20] | English: | AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA | [2019/20] | French: | ADMINISTRATION DE GÈNE À MÉDIATION PAR AAV2 DE SFASL COMME THÉRAPIE NEUROPROTECTRICE DANS LE GLAUCOME | [2019/20] | Entry into regional phase | 28.01.2019 | National basic fee paid | 28.01.2019 | Search fee paid | 28.01.2019 | Designation fee(s) paid | 28.01.2019 | Examination fee paid | Examination procedure | 28.01.2019 | Examination requested [2019/20] | 19.08.2020 | Amendment by applicant (claims and/or description) | 21.01.2021 | Despatch of a communication from the examining division (Time limit: M06) | 23.07.2021 | Reply to a communication from the examining division | 09.11.2022 | Despatch of a communication from the examining division (Time limit: M04) | 17.03.2023 | Reply to a communication from the examining division | 24.01.2024 | Communication of intention to grant the patent | 23.05.2024 | Fee for grant paid | 23.05.2024 | Fee for publishing/printing paid | 23.05.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 29.07.2019 | Renewal fee patent year 03 | 27.07.2020 | Renewal fee patent year 04 | 27.07.2021 | Renewal fee patent year 05 | 27.07.2022 | Renewal fee patent year 06 | 27.07.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2015044462 (SANOFI SA [FR], et al); | International search | [Y]US2002192823 (BARTLETT JEFFREY S [US]); | [Y]US2009239240 (CHU KETING [US]); | [A]US2011217760 (ATKINSON ANTHONY [GB], et al); | [A]US2013209395 (WEINER DAVID B [US], et al); | [Y]US2015044237 (TAUPIN JEAN-LUC [FR], et al); | [XY]US2016017005 (ASOKAN ARAVIND [US], et al) | by applicant | US5399363 | US5478745 | US5543158 | US5641515 | WO9810088 | US6001650 | US6156303 | US2003138772 |